Results 51 to 60 of about 4,829 (180)
BTK inhibition reprograms macrophages to suppress IL‐6/IL‐8/IL‐10‐driven CRS without compromising BsAb efficacy. ABSTRACT Bispecific antibodies (BsAbs) have shown marked efficacy in relapsed or refractory (R/R) B‐cell non‐Hodgkin lymphoma (B‐NHL). However, their clinical utility is constrained by cytokine release syndrome (CRS).
Jiaowu Cao +8 more
wiley +1 more source
Bruton Tyrosine Kinase Inhibitors
Abstract Bruton tyrosine kinase (BTK) is a nonreceptor tyrosine kinase that plays a central role in the signal transduction of the B-cell antigen receptor and other cell surface receptors, both in normal and malignant B lymphocytes.
openaire +3 more sources
T‐Cell Response After SARS‐CoV‐2 Vaccination in Patients With Hematological Malignancy
ABSTRACT Patients with hematologic malignancies (HM) often mount poor humoral responses to SARS‐CoV‐2 vaccination due to their immunocompromised status. Protection against severe COVID‐19 is strongly related to cellular immunity, yet vaccine‐induced T‐cell responses remain incompletely characterized.
L. S. Boerenkamp +7 more
wiley +1 more source
Abstract Autoimmune haemolytic anaemia is a rare immune‐mediated disorder leading to accelerated red cell destruction and anaemia. There is considerable clinical heterogeneity, with some patients barely requiring intervention, while others experience fulminant haemolysis and experience mortality rates as high as 30% with severe anaemia and end‐organ ...
Philip Choi +9 more
wiley +1 more source
The Potential Therapeutic Role of Bruton Tyrosine Kinase Inhibition in Neurodegenerative Diseases
Bruton Tyrosine Kinase (BTK) has emerged as a critical mediator in the pathophysiology of neuroinflammation associated with neurodegenerative diseases.
Francesco D’Egidio +5 more
doaj +1 more source
Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran +2 more
wiley +1 more source
Autoimmune hemolytic anemia in the era of immunotherapy: from pathogenesis to therapeutic strategies
Autoimmune hemolytic anemia (AIHA) is a rare hematologic disorder characterized by the accelerated destruction of red blood cells mediated by autoantibodies and is classified into warm antibody type and cold antibody type.
Sijia Yan, Jiaying Wu, Mi Zhou, Yi Xiao
doaj +1 more source
Management of chronic urticaria: Current status and future prospect
Chronic urticaria is driven by mast cell activation through autoimmune, inflammatory, and neuroimmune pathways. A structured approach combining diagnosis, patient‐reported outcomes, stepwise therapy, treatment optimization, monitoring and emerging targeted agents may improve disease control and enable more personalized management.
Andaç Salman +15 more
wiley +1 more source
Background Although chronic lymphocytic leukemia (CLL) typically follows an indolent course involving blood, lymph nodes, and bone marrow, extranodal organ involvement is rare and poorly characterized. Methods We retrospectively analyzed 19 patients with
Finn J. Schulze +8 more
doaj +1 more source
Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab
Rituximab‐refractory pemphigus vulgaris is driven by B‐cell repopulation, plasma‐cell persistence, IgG4 autoantibodies and anti‐drug antibodies. This review evaluates five emerging targeted classes acting at successive steps of disease: next‐generation anti‐CD20 antibodies, DSG3‐CAAR T cells, BTK inhibitors, BAFF/APRIL inhibitors and FcRn antagonists ...
Rhea Ahuja, Dedee Murrell
wiley +1 more source

